87E.F Dianthus Therapeutics, Inc.
- Market cap
- EUR 4.42B
- P/E
- -
- P/B
- 4.02x
- ROE
- -14.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 87E.F undervalued?
Graham numberThe Graham number of Dianthus Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dianthus Therapeutics, Inc. fundamental analysis
No fundamental analysis for Dianthus Therapeutics, Inc. yet.
Dianthus Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production…
Full company profileDianthus Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dianthus Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M | 3.25M |
| Operating Income | -13.1M | -29.7M | -48.2M | -102M | -178M | -222M |
| EBITDA | - | -29.6M | -47.8M | -101M | -178M | -222M |
| Net Income | -13.1M | -28.5M | -43.6M | -85.0M | -162M | -184M |
| EPS | -0.88 | -1.92 | -2.94 | -2.73 | -3.76 | -3.26 |
| Balance Sheet | ||||||
| Total Assets | 9.45M | 83.1M | 179M | 374M | 531M | 1.28B |
| Total Liabilities | 26.7M | 9.45M | 10.5M | 21.5M | 37.5M | 34.8M |
| Shareholders' Equity | -17.2M | 73.7M | 169M | 352M | 493M | 1.24B |
| Cash & Short-term Investments | 7.64M | 15.4M | 132M | 22.8M | 51.1M | 55.7M |
| Cash Flow | ||||||
| Operating Cash Flow | -9.90M | -29.1M | -36.9M | -78.2M | -129M | -171M |
| Capital Expenditure | 33.0K | 139K | 110K | 105K | 213K | 745K |
| Free Cash Flow | -9.94M | -29.2M | -37.0M | -78.3M | -129M | -172M |
| Ratios | ||||||
| ROE | - | -38.7% | -25.8% | -24.1% | -32.9% | -14.8% |
| ROA | -138.7% | -34.3% | -24.3% | -22.7% | -30.6% | -14.4% |
| Net Profit Margin | -888.1% | -443.8% | -1,541.2% | -1,362.8% | -7,973.3% | -5,657.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Dianthus Therapeutics, Inc. dividends
Dianthus Therapeutics, Inc. has not paid dividends in the last 5 fiscal years.
Who owns Dianthus Therapeutics, Inc.
- Insiders 0.12%
- Institutions 99.88%
- Public & others 0.00%
- Shares outstanding 56.3M
- Free float 56.2M
Dianthus Therapeutics, Inc. company profile
- Company name
- Dianthus Therapeutics, Inc.
- Ticker
- 87E.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 92
- Fiscal year end
- December
- Address
- 7 Times Square, New York, NY, United States, 10036
- Phone
- 929 999 4055
- Website
- dianthustx.com
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Dianthus Therapeutics, Inc. management
10- Mr. Marino Garcia M.B.A.President, CEO & Director · born 1966
- Mr. Ryan SavitzExecutive VP, CFO, Chief Business Officer & Treasurer · born 1989
- Dr. Simrat Randhawa M.B.A., M.D.Executive VP and Head of R&D · born 1970
- Mr. Edward G. CarrSenior VP & Chief Accounting Officer · born 1969
- Mr. Judson TaylorSenior VP & Head of Technical Operations
- Ms. Jennifer Davis RuffVP and Head of Investor Relations & Corporate Affairs
- Mr. Adam M. Veness Esq.Senior VP, General Counsel & Secretary · born 1986
- Ms. Kristina MaximenkoChief People Officer
- Ms. Rashieda GluckHead of Clinical Development Operations
- Mr. Scott Nogi M.B.A.Head of Business Operations